Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia
نویسندگان
چکیده
منابع مشابه
V2 Receptor Antagonist; Tolvaptan
Hyponatremia is the most common electrolyte disorder in hospitalized patients. Many studies documented that it was related to increased morbidity and mortality in patients with congestive heart failure, liver cirrhosis, and neurologic diseases. Although knowledge of hyponatremia has been cumulated, the optimal management of hyponatremia remains incompletely established in clinical practice beca...
متن کاملUse of oral vasopressin V2 receptor antagonist for hyponatremia in acute brain injury.
a Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul , Republic of Korea; b Departments of Neurosurgery and Neurology, The University of Texas Medical School at Houston, Houston, Tex. , c Department of Neurology, University of Maryland School of Medicine, Baltimore, Md. , and Departments of d Neurology and e Pharmacy, Columbia University College of Phys...
متن کاملCharacterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
SR 121463A, a potent and selective, orally active, nonpeptide vasopressin V2 receptor antagonist, has been characterized in several in vitro and in vivo models. This compound displayed highly competitive and selective affinity for V2 receptors in rat, bovine and human kidney (0.6 < or = Ki [nM] < or = 4.1). In this latter preparation, SR 121463A potently antagonized arginine vasopressin (AVP)-s...
متن کاملOral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension.
During the past decade, the prognosis of patients with pulmonary hypertension (PH) has improved due to the development of pulmonary arterial vasodilators [1]. Yet, treatment for right-sided heart failure (RHF) associated with PH has not improved, despite being the most important prognostic factor for chronic RHF [2, 3]. Existing treatment strategies for RHF associated with PH are restricted to ...
متن کاملAn overview of satavaptan: a selective V2 receptor antagonist
The increasing recognition of the risk of hyponatremia and its public health impact [1–4] has been matched by increasing interest in the new class of drugs, proven to correct hyponatremia, the arginine vasopressin (AVP) V2 receptor antagonists (so-called vaptans). Two vaptans have already been approved for the management of hyponatremia in the USA, and considerable research efforts have been de...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2006
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmoa065181